A Phase I Study Of OSI-774 (NSC #718781)-Based Multimodality Therapy For Inoperable Stage III Non Small Cell Lung Cancer

Trial Profile

A Phase I Study Of OSI-774 (NSC #718781)-Based Multimodality Therapy For Inoperable Stage III Non Small Cell Lung Cancer

Discontinued
Phase of Trial: Phase I

Latest Information Update: 31 Jan 2013

At a glance

  • Drugs Erlotinib (Primary) ; Carboplatin; Cisplatin; Docetaxel; Etoposide; Paclitaxel
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 31 Jan 2013 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
    • 29 Aug 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top